Selective concomitant inhibition of mTORC1 and mTORC2 activity in estrogen receptor negative breast cancer cells by BN107 and oleanolic acid

International Journal of Cancer

Volumn 127, Issue 5, 2010, Pages 1209-1219

  Chu, Ruth ^a   Zhao, Xiaoyue ^a   Griffin, Chandi ^b   Staub, Richard E ^a   Shoemaker, Mark ^a   Climent, Joan ^c   Leitman, Dale ^b   Cohen, Isaac ^a   Shtivelman, Emma ^a   Fong, Sylvia ^a  

^a Bionovo Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; ER ; Lipid raft; mTORC1; mTORC2; Oleanolic acid

Indexed keywords

BN 107; CHOLESTEROL; ESTROGEN RECEPTOR ALPHA; LIPID; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; OLEANOLIC ACID; OLEANOLIC ACID DERIVATIVE; UNCLASSIFIED DRUG; CRTC2 PROTEIN, HUMAN; CYTOCHROME C; ESTROGEN RECEPTOR BETA; MTORC1 PROTEIN, HUMAN; PLANT EXTRACT; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HUMAN CELL; LIPID RAFT; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; BREAST TUMOR; CELL MEMBRANE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GLEDITSIA; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CHOLESTEROL; CYTOCHROMES C; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLEDITSIA; HUMANS; MEMBRANE MICRODOMAINS; MEMBRANE POTENTIAL, MITOCHONDRIAL; OLEANOLIC ACID; PLANT EXTRACTS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 77955488394     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25116     Document Type: Article

References (61)

1. Cheung F, Chui CH, Chan AS, Lau FY, Cheng GY, Wong RS, Kok SH, Teo IT, Cheng CH, Tang JC. Inhibition of proteasome activity in Gleditsia sinensis fruit extract-mediated apoptosis on human carcinoma cells. Int J Mol Med 2005;16:925-9.
2. Chui CH, Lau FY, Chan AS, Cheng GY, Wong RS, Lai KB, Kok SH, Yeung TT, Teo IT, Yau MY, Cheung F, Cheng CH, et al. Gleditsia sinensis fruit extract-induced apoptosis involves changes of reactive oxygen species level, mitochondrial membrane depolarization and caspase 3 activation. Int J Mol Med 2005;15:539-43.
3. Pak KC, Lam KY, Law S, Tang JC. The inhibitory effect of Gleditsia sinensis on cyclooxygenase-2 expression in human esophageal squamous cell carcinoma. Int J Mol Med 2009;23:121-9.
4. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res 2005;19:649-51.
5. Zhong L, Li P, Han J, Qu G, Guo D. Structure-activity relationships of saponins from Gleditsia sinensis in cytotoxicity and induction of apoptosis. Planta. Med. 2004;70:797-802.
6. Hsu HY, Yang JJ, Lin CC. Effects of oleanolic acid and ursolic acid on inhibiting tumor growth and enhancing the recovery of hematopoietic system postirradiation in mice. Cancer Lett 1997;111:7-13.
7. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69.
8. Melzig MF, Bader G, Loose R. Investigations of the mechanism of membrane activity of selected triterpenoid saponins. Planta Med 2001;67:43-8.
9. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31-9.
10. Zidovetzki R, Levitan I. Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochim Biophys Acta 2007;1768:1311-24.
11. Patra SK. Dissecting lipid raft facilitated cell signaling pathways in cancer. Biochim Biophys Acta 2008;1785:182-206.
12. Anderson RG Transendothelial movement and caveolae. Nat Biotechnol 2008;26:380-1; author reply 1-2.
13. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K, Solomon KR, Freeman MR. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007;67:6238-46.
14. Fedida-Metula S, Elhyany S, Tsory S, Segal S, Hershfinkel M, Sekler I, Fishman D. Targeting lipid rafts inhibits protein kinase B by disrupting calcium homeostasis and attenuates malignant properties of melanoma cells. Carcinogenesis 2008;29:1546-54.
15. Asaki C, Usuda N, Nakazawa A, Kametani K, Suzuki T. Localization of translational components at the ultramicroscopic level at postsynaptic sites of the rat brain. Brain Res 2003;972:168-76.
16. Partovian C, Ju R, Zhuang ZW, Martin KA, Simons M. Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells. Mol Cell 2008;32:140-9.
17. Akkiprik M, Nicorici D, Cogdell D, Jia YJ, Hategan A, Tabus I, Yli-Harja O, Y D, Sahin A, Zhang W. Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol Cancer Res Treat 2006;5:543-51.
18. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN. The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 2008.
19. Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008;12:1139-65.
20. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
21. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344 Pt 2:427-31.
22. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 2006;25:6373-83.
23. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
24. Huang J, Manning BD. A complex interplay between Akt. TSC2 and the two m. TOR complexes. Biochem Soc Trans 2009;37:217-22.
25. Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 2007;405:513-22.
26. Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 2008;416:375-85.
27. Alessi DR, Pearce LR, Garcia-Martinez JM. New insights into mTOR signaling: mTORC2 and beyond. Sci Signal 2009;2:pe27.
28. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
29. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
30. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
31. Copp J, Manning G, Hunter T. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009;69:1821-7.
32. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;28:1119-32.
33. Le Tourneau C, Faivre S, Serova M, Raymond E. mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008;99:1197-203.
34. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
35. Maira SM, Stauffer F, Schnell C, Garcia-Echeverria C. PI3K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans 2009;37:265-72.
36. King FW, Fong S, Griffin C, Shoemaker M, Staub R, Zhang YL, Cohen I, Shtivelman E Timosaponin AIII is preferentially cytotoxic to tumor cells through inhibition of mTOR and induction of ER stress. PloS one 2009;4:e7283.
37. Ostapkowicz A, Inai K, Smith L, Kreda S, Spychala J. Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor. Mol Cancer Ther 2006;5:238-45.
38. Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J, Michalides R. Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol 2009;23:1335-45.
39. Petrel TA, Brueggemeier RW. Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-beta1 in breast cancer cell lines. J Cell Biochem 2003;88:181-90.
40. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55.
41. Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids 2002;37:185-92.
42. Mitsumasa Haruna M, Sugimoto T, Kojima R, Suzuki Y, Konoshima T, Kozuka M, Ito K. Alteration of Na+ permeability in human erythrocytes as studied by 23Na-NMR and inhibition of the kidney Na+,K+-ATPase activities with saponins: interaction of gleditsia saponins with human erythrocyte membranes. Bioorg Med Chem Lett 1995;5:827-30.
43. Fong S, Shoemaker M, Cadaoas J, Lo A, Liao W, Tagliaferri M, Cohen I, Shtivelman E. Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells. Cancer Biol Ther 2008;7:577-86.
44. Lee JL, Wang MJ, Sudhir PR, Chen JY. CD44 engagement promotes matrix-derived survival through the CD44-SRC-integrin axis in lipid rafts. Mol Cell Biol 2008;28:5710-23.
45. Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003;285:L1179-83.
46. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 2007;99:129-40.
47. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F, Speed T, Spellman PT, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
48. McClelland RA, Gee JM, Francis AB, Robertson JF, Blamey RW, Wakeling AE, Nicholson RI Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur J Cancer 1996;32A:413-6.
49. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004;378:281-92.
50. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009;7:e38.
51. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009;284:8023-32.
52. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-5.
53. Foster DA, Toschi A. Targeting mTOR with rapamycin: one dose does not fit all. Cell Cycle 2009;8:1026-9.
54. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009;29:1411-20.
55. Di Vizio D, Solomon KR, Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 2008;94:633-9.
56. Swyer G. The cholesterol content of normal and enlarged prostates. Cancer Res 1942;2:372-5.
57. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 2005;16:273-9.
58. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005;438:612-21.
59. Szejtli J, Szente L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur J Pharm Biopharm 2005;61:115-25.
60. Jacobson K, Mouritsen OG, Anderson RG. Lipid rafts: at a crossroad between cell biology and physics. Nat Cell Biol 2007;9:7-14.
61. Rajendran L, Masilamani M, Solomon S, Tikkanen R, Stuermer CA, Plattner H, Illges H. Asymmetric localization of flotillins/reggies in preassembled platforms confers inherent polarity to hematopoietic cells. Proc Natl Acad Sci USA 2003;100:8241-6.